KLK3 and prostate carcinoma: The present study further demonstrated the effectiveness of adjuvant goserelin 10.8-mg depot after an RP in suppressing serum testosterone and PSA levels in patients with localized or locally advanced prostate cancer (Figures S1 and S2).